Clinical Trials Logo

Neuroendocrine clinical trials

View clinical trials related to Neuroendocrine.

Filter by:
  • None
  • Page 1

NCT ID: NCT02038738 Not yet recruiting - Clinical trials for Neuroendocrine Carcinoma

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

NCT ID: NCT01169649 Completed - PANCREAS Clinical Trials

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer. MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.

NCT ID: NCT01149434 Terminated - Cancer Clinical Trials

Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The study consists of two parts: Drug Interaction (Pharmacokinetic) Phase and Pharmacodynamic Phase The primary study objective for the Drug Interaction Study is to determine the pharmacokinetic interactions between RAD001 and JI-101. The primary study objective for the Pharmacodynamic Study is progression-free survival at 2 moths, evaluated separately in each of the three cohorts. These will include a determination of tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria and an assessment of ephrinB4 expression in blood samples. Secondary objectives are to determine safety and tolerability of JI-101. The investigational products are everolimus (42-O-(2-hydroxyethyl) rapamycin) and JI-101 (1-[1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl]-3-(5-bromo-2 methoxy-phenyl)-urea) Eligible patients meeting all study entry criteria will be enrolled in the study. For the Drug Interaction study, patients with solid tumors will receive a single dose (10 mg) of Everolimus by mouth on Day 1 and Day 8 and JI-101 capsules (200 mg) by mouth on Day 8 and Day 15. For the Pharmacodynamic Study, all patients will receive JI-101 capsules by mouth (200 mg BID) for 28 day treatment cycles.

NCT ID: NCT00688623 Completed - Carcinoma Clinical Trials

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe

RAMSETE/CDE16
Start date: June 24, 2009
Phase: Phase 2
Study type: Interventional

To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.

NCT ID: NCT00314925 Active, not recruiting - Carcinoid Clinical Trials

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Start date: April 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.